Ciba's Vivelle
Executive Summary
Transdermal estrogen skin patch for moderate-to-severe menopausal symptoms approved by FDA Oct. 28. The product was approved in four dosages: .0375, .05, .075, .1 mg per day delivered via a translucent patch attached to the abdomen or buttocks that is replaced twice per week. The active ingredient, 17-beta estradiol, is embedded in the adhesive. Ciba notes that the product allows for more flexible dosing than its other transdermal estrogen replacement product, Estraderm. In addition, Vivelle is thinner and has better adhesion than the earlier product. Unlike Estraderm, Vivelle is not indicated for postmenopausal osteoporosis. Vivelle was developed by Miami-Fla.- based Noven Pharmaceuticals. The product will be available in the U.S. in 1995
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth